Health and Disability Ethics Committees
Ministry of Health
133 Molesworth Street
PO Box 5013
Wellington
6011

0800 4 ETHICS
hdecs@health.govt.nz

17 September 2020

Professor Richard Beasley
Medical Research Institute of New Zealand
Private Bag 7902
Newtown
Wellington 6242

Dear Professor Beasley

Re:	**Ethics ref:**	**20/NTB/200**
	Study title:	An open-label Randomised Controlled Trial of as-needed budesonide-formoterol vs salbutamol reliever therapy in mild childhood asthmaa

I am pleased to advise that this application has been *approved* by the Northern B Health and Disability Ethics Committee. This decision was made through the HDEC-Full Review pathway.

Summary of outstanding ethical issues

The main ethical issues considered by the Committee which require addressing by the Researcher are as follows.

1. The Committee queried how participants would be identified. The Researcher stated through a database and local GP practices could identify potential participants and send them information about the study. The Researcher confirmed they would not approach patients or access their medical records directly.

2. The Committee queried the safety protocol for if a young person disclosed, they were pregnant. The Researcher stated they would follow the local child safeguard procedures at the site level and at the very least would insist on the need to inform the GP. The Researcher stated if the young person smoked, they would additionally provide smoking cessation advice.

3. The Committee queried whether AstraZeneca would have access to the source data. The Researcher stated they were unsure and would provide clarification.

4. Please simplify the language in the consent clauses for the 12-15-year-old consent form.

5. Please insert the name and address of the Sponsor into the header on the first page of the PIS.

Conditions of HDEC approval

HDEC approval for this study is subject to the following conditions being met prior to the commencement of the study in New Zealand. It is your responsibility, and that of the study's sponsor, to ensure that these conditions are met. No further review by the Northern B Health and Disability Ethics Committee is required.

Standard conditions:

1. Before the study commences at *any* locality in New Zealand, all relevant regulatory approvals must be obtained.

2. Before the study commences at *any* locality in New Zealand, it must be registered in a clinical trials registry. This should be a WHO-approved registry (such as the Australia New Zealand Clinical Trials Registry, www.anzctr.org.au) or https://clinicaltrials.gov/.

3. Before the study commences at *each given* locality in New Zealand, it must be authorised by that locality in Online Forms. Locality authorisation confirms that the locality is suitable for the safe and effective conduct of the study, and that local research governance issues have been addressed.

After HDEC review

Please refer to the *Standard Operating Procedures for Health and Disability Ethics Committees* (available on www.ethics.health.govt.nz) for HDEC requirements relating to amendments and other post-approval processes.

Your next progress report is due by 17 September 2021.

As your study is an intervention study involving a new medicine, all progress reports must be accompanied by an annual safety report. While there is no prescribed format for annual safety reports, they must be no longer than two pages in length, written in lay language, and include a brief description and analysis of:

- new and relevant findings that may have a significant impact on the safety of participants
- the safety profile of the new medicine and its implications for participants, taking into account all safety data as well as the results of any relevant non-clinical studies
- the implications of safety data to the risk-benefit ratio for the intervention study, and whether study documentation has been or will be updated
- any measures taken or proposed to minimise risks. (Where such a proposed measure would be a substantial amendment, it must be submitted for HDEC review in the normal way)

For the avoidance of doubt, Development Safety Update Reports (DSURs) may serve as annual safety reports to HDECs provided that they contain the information outlined above. These summaries should usually be accompanied by comment from the New Zealand CI of the study.

Please refer to the *Standard Operating Procedures for Health and Disability Ethics Committees* paragraphs 206 - 208 for further information.

Participant access to ACC

The Northern B Health and Disability Ethics Committee is satisfied that your study is not a clinical trial that is to be conducted principally for the benefit of the manufacturer or distributor of the medicine or item being trialled. Participants injured as a result of treatment received as part of your study may therefore be eligible for publicly-funded compensation through the Accident Compensation Corporation (ACC).

Please don't hesitate to contact the HDEC secretariat for further information. We wish you all the best for your study.

Yours sincerely,



Chairperson
Northern B Health and Disability Ethics Committee

Encl: appendix A: documents submitted
appendix B: statement of compliance and list of members

Appendix A
Documents submitted

Document	*Version*	*Date*	
Survey/questionnaire: Asthma Control Questionnaire (ACQ-5)	1	22 September 2017	
Evidence of scientific review: Peer review by Dr Louise Fleming	1	10 June 2020	
CV for CI: Prof Richard Beasley CV	1	10 August 2020	
CVs for other Investigators: Dr Lee Hatter CV	1	13 August 2020	
CVs for other Investigators: Dr Ciléin Kearns CV	1	18 August 2020	
CARE Asthma Action Plan - ICS-LABA Step 1	1	19 August 2020	
CARE Asthma Action Plan - ICS-LABA Steps 2-3	1	19 August 2020	
CARE Asthma Action Plan - SABA Step 1	1	19 August 2020	
CARE Asthma Action Plan - SABA Step 2-3	1	19 August 2020	
Evidence of CI indemnity	1	19 August 2020	
CARE advertising word and image options	1	19 August 2020	
CARE study example advert (poster)	1	19 August 2020	
CARE GP Correspondence v1.0	1	19 August 2020	
CARE GP mail out letter	1	19 August 2020	
Protocol: CARE Study protocol v1.0	1	19 August 2020	
MyCap screenshots	1	20 August 2020	
PIS/CF: CARE PIS-AF 5-6yrs	1	19 August 2020	
PIS/CF: CARE PIS-AF 5-6yrs	1	19 August 2020	
PIS/CF: CARE PIS-AF 12-15yrs	1	19 August 2020	
Investigator's Brochure: Investigator's Brochure for Symbicort Rapihaler 50/3	1	25 July 2010	
Evidence of scientific review: HRC Peer Review Report #1	1	05 June 2020	
Evidence of scientific review: HRC Peer Review Report #2	1	05 June 2020	
Evidence of scientific review: HRC Peer Review Report #3	1	05 June 2020	
Evidence of scientific review: HRC Peer Review Report #4	1	05 June 2020	
PIS/CF: Sub-study PIS-CF-AF	1	19 August 2020	
PIS/CF: Comic cover page for intervention arm of sub-study	1	19 August 2020	
Protocol: CAREtoon substudy protocol	1	20 August 2020	
Covering Letter: Cover letter	1	19 August 2020	
PIS/CF for persons interested in welfare of non-consenting participant: PIS-CF (parent/guardian)	1	19 August 2020	
Application		20 August 2020	

Appendix B
Statement of compliance and list of members

Statement of compliance

The Northern B Health and Disability Ethics Committee:

- is constituted in accordance with its Terms of Reference
- operates in accordance with the *Standard Operating Procedures for Health and Disability Ethics Committees*, and with the principles of international good clinical practice (GCP)
- is approved by the Health Research Council of New Zealand's Ethics Committee for the purposes of section 25(1)(c) of the Health Research Council Act 1990
- is registered (number 00008715) with the US Department of Health and Human Services' Office for Human Research Protection (OHRP).

List of members

Name	*Category*	*Appointed*	*Term Expires*
Mr John Hancock	Lay (the law)	14/12/2015	14/12/2018
Dr Nora Lynch	Non-lay (health/disability service provision)	19/03/2019	19/03/2026
Miss Tangihaere Macfarlane	Lay (consumer/community perspectives)	20/05/2017	20/05/2020
Mrs Kate O'Connor	Lay (ethical/moral reasoning)	14/12/2015	14/12/2018
Mrs Stephanie Pollard	Non-lay (intervention studies)	01/07/2015	01/07/2018
Mrs Leesa Russell	Non-lay (intervention studies), Non-lay (observational studies)	14/12/2015	14/12/2018
Ms Susan Sherrard	Lay (consumer/community perspectives)	19/03/2019	19/03/2022
Mrs Jane Wylie	Non-lay (intervention studies)	20/05/2017	20/05/2020

Unless members resign, vacate or are removed from their office, every member of HDEC shall continue in office until their successor comes into office (HDEC Terms of Reference)

http://www.ethics.health.govt.nz